Medidata today announced that it has entered into a definitive agreement to acquire SHYFT Analytics for $195 million in cash, closing the loop on clinical development with commercial and real-world data analytics. SHYFT Analytics cloud data analytics platform for life sciences provides insights on 45B patient records and 2M providers. Medidata’s unified platform, pioneering analytics, and unrivaled expertise power the development of new therapies for over 1,000 pharmaceutical companies, biotech, medical device firms, academic medical centers and contract research organizations around the world.
Once the acquisition is closed, the combined platform seamlessly delivers market-leading applications, services, and proven data science capabilities, powered by the largest global pool of research data, companies’ own CRM data, 3rd party commercial data, and real-world data sources.
Closing The Loop on Clinical & Commercial Insights
Pharmaceutical, biotech, and medical device companies now have an unprecedented ability to manage and optimize value across the clinical and commercial continuum. The new Intelligent Platform for Life Sciences significantly enhances drug and device discovery, development and commercialization by:
– Accelerating value: Demonstrate efficacy and safety, obtain regulatory approval, and achieve peak revenue faster
– Minimizing risk: De-risk the planning and execution of clinical development and commercialization strategies
– Optimizing outcomes: Provide the best possible outcomes for patients, providers, and payers with increasingly precise therapies
“SHYFT and Medidata share a common vision to transform how life science companies harness the value of data to advance enterprise decision-making and patient outcomes,” said SHYFT CEO and Founder, Zack King. “Our talented team has had great success delivering value to the industry and our combined technology will create something unique that will unlock enormous opportunities for our customers. We are thrilled to be joining forces with Medidata to further execute our mission to advance healthcare through analytics.”
The acquisition has been unanimously approved by the Boards of Directors of each company and the stockholders of SHYFT, and is expected to close in the second quarter of 2018, subject to customary closing conditions.
